Nuvalent to Unveil Key Data for Neladalkib and Zidesamtinib at ASCO 2026
Event summary
- Nuvalent will present pivotal data for neladalkib in ALK-positive NSCLC at ASCO 2026 on May 29.
- Preliminary data for zidesamtinib in ROS1-positive solid tumors will be shared on May 30.
- Neladalkib has FDA breakthrough therapy designation for ALK-positive NSCLC.
- Zidesamtinib's NDA submission has a PDUFA target action date of September 18, 2026.
The big picture
Nuvalent's presentations at ASCO 2026 come as the biopharmaceutical company aims to differentiate its kinase-targeted therapies in a competitive oncology landscape. The focus on brain-penetrant, selective inhibitors addresses key limitations of current treatments, potentially expanding options for patients with resistant tumors. The strategic emphasis on overcoming resistance and minimizing adverse events aligns with broader industry trends toward more precise and durable cancer therapies.
What we're watching
- Clinical Efficacy
- How the pivotal data for neladalkib will position it against existing ALK inhibitors in the market.
- Regulatory Pathway
- Whether the FDA will approve zidesamtinib by the September 2026 PDUFA date.
- Market Differentiation
- The pace at which Nuvalent can establish neladalkib and zidesamtinib as preferred treatments for resistant cancer types.
Related topics